Our current understanding of the molecular mechanisms driving prostate cancer onset and progression is growing rapidly. In order to help dissect the genetic and biochemical events that lead to prostatic disease several mouse models such as the PTEN +/- KO and TRAMP lines have been engineered which produce non-invasive PIN and metastatic cancers respectively. Since PSA and hK2 can provide interesting clinical information during screening, treatment, and follow-up, we aim to develop these two mouse models further to also include the genes KLK3 and KLK2 which encode PSA/ hK3 and hK2 protein respectively.
